NCT01700270View on ClinicalTrials.gov

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
DRUG

dovitinib (TKI258)

DRUG

fluvoxamine

perpetrator drug; 7 days of dosing

Trial Locations (6)

1211

Novartis Investigative Site, Geneva

7000

Novartis Investigative Site, Chur

10467

Montefiore Medical Center Montefiore Medical Center (SC), The Bronx

78229

Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio

DK-2100

Novartis Investigative Site, Copenhagen

1066 CX

Novartis Investigative Site, Amsterdam

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY